These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 29414305)

  • 1. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
    Wu J; Waxman DJ
    Cancer Lett; 2018 Apr; 419():210-221. PubMed ID: 29414305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
    Vergato C; Doshi KA; Roblyer D; Waxman DJ
    Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.
    Lai V; Neshat SY; Rakoski A; Pitingolo J; Doloff JC
    Adv Drug Deliv Rev; 2021 Dec; 179():113920. PubMed ID: 34384826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy.
    Robertson-Tessi M; El-Kareh A; Goriely A
    J Theor Biol; 2015 Sep; 380():569-84. PubMed ID: 26087282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy and Anticancer Immune Responses].
    Harada M
    Gan To Kagaku Ryoho; 2016 May; 43(5):571-7. PubMed ID: 27210085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments.
    Pusuluri A; Wu D; Mitragotri S
    J Control Release; 2019 Jul; 305():130-154. PubMed ID: 31004668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay of immunotherapy and chemotherapy: harnessing potential synergies.
    Emens LA; Middleton G
    Cancer Immunol Res; 2015 May; 3(5):436-43. PubMed ID: 25941355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inducers of immunogenic cell death for tumor immunotherapy.
    Li X
    Tumori; 2018; 104(1):1-8. PubMed ID: 28967094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer.
    Gebremeskel S; Lobert L; Tanner K; Walker B; Oliphant T; Clarke LE; Dellaire G; Johnston B
    Cancer Immunol Res; 2017 Dec; 5(12):1086-1097. PubMed ID: 29054890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy.
    Jiang M; Zeng J; Zhao L; Zhang M; Ma J; Guan X; Zhang W
    Nanoscale; 2021 Oct; 13(41):17218-17235. PubMed ID: 34643196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.
    Abu Eid R; Razavi GS; Mkrtichyan M; Janik J; Khleif SN
    Cancer Immunol Res; 2016 May; 4(5):377-82. PubMed ID: 27196429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.